News Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-13 pm EDT			5-day change	1st Jan Change
977 ^USD	+0.32%		+1.91%	+11.23%

May. 13	Regeneron, Sanofi Get Speedy FDA Review of Dupixent in Younger CRSwNP Group	DJ
May. 13	Regeneron Pharmaceuticals, Sanofi Say FDA Accepts Dupixent Supplemental Application for Priority Review	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Regeneron, Sanofi Get Speedy FDA Review of Dupixent in Younger CRSwNP Group	May. 13	DJ
Regeneron Pharmaceuticals, Sanofi Say FDA Accepts Dupixent Supplemental Application for Priority Review	May. 13	MT
The Interplay: Key Decisions At The Intersection Of Antitrust & Life Sciences - April 2024	May. 13	AQ
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)	May. 13	GL
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)	May. 13	AQ
REGENERON PHARMACEUTICALS - LATEST DB-OTO RESULTS SHOW DRAMATICALLY IMPROVED HEARING TO NORMAL LEVELS IN A CHILD WITH PROFOUND GENETIC DEAFNESS WITHIN 24 WEEKS AND INITIAL HEARING IMPROVEMENTS IN A SECOND CHILD AT 6 WEEKS	May. 09	AQ
Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks	May. 08	GL
Regeneron Pharmaceuticals, Inc. Announces Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness Within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks	May. 08	CI
UBS Raises Regeneron Pharmaceuticals Price Target to $1,124 From $1,099, Maintains Buy Rating	May. 07	MT
Regeneron Announces Investor Conference Presentations	May. 06	GL
Deutsche Bank Adjusts Price Target on Regeneron Pharmaceuticals to $870 From $880, Hold Rating Kept	May. 03	MT
Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $1,180 From $1,126	May. 03	MT
Morgan Stanley Raises Price Target on Regeneron Pharmaceuticals to $1,183 From $1,177	May. 02	MT
Piper Sandler Adjusts Regeneron Pharmaceuticals' Price Target to $1,000.25 From $1,016	May. 02	MT
RBC Cuts Price Target on Regeneron Pharmaceuticals to $1,185 From $1,189	May. 02	MT
Global markets live: Etsy, Qualcomm, Carvana, Rio Tinto, Apple...	May. 02
Sector Update: Health Care Stocks Mixed Premarket Thursday	May. 02	MT
Regeneron Pharmaceuticals : May 2024 Corporate Presentation	May. 02	PU
Transcript : Regeneron Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 02, 2024	May. 02
Regeneron: Adjusted EPS down 4% in Q1	May. 02	CF

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Summary

Filters